In summary, this study, the largest monotherapy trial using a PCSK9 inhibitor to date, showed that evolocumab significantly reduces LDL-C plasma levels compared with placebo or ezetimibe and is well tolerated in patients with hypercholesterolemia. Here, PCSK9 is linked to Hypercholesterolemia.